These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21925434)

  • 1. Imaging surrogate end points in heart failure trials.
    Bettari L; Borges-Neto S
    Heart Fail Clin; 2011 Oct; 7(4):509-18. PubMed ID: 21925434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers as surrogate end points in heart failure trials.
    Felker GM
    Heart Fail Clin; 2011 Oct; 7(4):501-7. PubMed ID: 21925433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. End-point selection for acute heart failure trials.
    Allen LA
    Heart Fail Clin; 2011 Oct; 7(4):481-95. PubMed ID: 21925431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogate end points in clinical research: hazardous to your health.
    Grimes DA; Schulz KF
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1114-8. PubMed ID: 15863552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.
    Powers JH
    Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiorenal syndrome clinical trial end points.
    Mentz RJ; O'Connor CM
    Heart Fail Clin; 2011 Oct; 7(4):519-28. PubMed ID: 21925435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical exacerbations as a surrogate end point in heart failure research.
    Sayers SL; Riegel B; Goldberg LR; Coyne JC; Samaha FF
    Heart Lung; 2008; 37(1):28-35. PubMed ID: 18206524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
    Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
    Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key issues in end point selection for heart failure trials: composite end points.
    Neaton JD; Gray G; Zuckerman BD; Konstam MA
    J Card Fail; 2005 Oct; 11(8):567-75. PubMed ID: 16230258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surrogate end points in secondary analyses of cardiovascular trials.
    Buhr KA
    Prog Cardiovasc Dis; 2012; 54(4):343-50. PubMed ID: 22226002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. End point selection in acute decompensated heart failure clinical trials: economic end points.
    Reed SD; Eapen ZJ; Schulman KA
    Heart Fail Clin; 2011 Oct; 7(4):529-37. PubMed ID: 21925436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers in Alzheimer's disease: not yet surrogate endpoints.
    Coley N; Andrieu S; Delrieu J; Voisin T; Vellas B
    Ann N Y Acad Sci; 2009 Oct; 1180():119-24. PubMed ID: 19906266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study.
    Bourge RC; Abraham WT; Adamson PB; Aaron MF; Aranda JM; Magalski A; Zile MR; Smith AL; Smart FW; O'Shaughnessy MA; Jessup ML; Sparks B; Naftel DL; Stevenson LW;
    J Am Coll Cardiol; 2008 Mar; 51(11):1073-9. PubMed ID: 18342224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are scores useful in advanced heart failure?
    Goldraich L; Beck-da-Silva L; Clausell N
    Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):985-97. PubMed ID: 19673676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure.
    Konstam MA
    Am J Cardiol; 2005 Sep; 96(6):867-71. PubMed ID: 16169379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative outcome measures for pediatric clinical sepsis trials.
    Curley MA; Zimmerman JJ
    Pediatr Crit Care Med; 2005 May; 6(3 Suppl):S150-6. PubMed ID: 15857550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
    Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
    J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study.
    Maisel A; Xue Y; Shah K; Mueller C; Nowak R; Peacock WF; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand IS; Ng L; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Terracciano G; Kremastinos D; Hartmann O; von Haehling S; Bergmann A; Morgenthaler NG; Anker SD
    Circ Heart Fail; 2011 Sep; 4(5):613-20. PubMed ID: 21765124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TEACH: Trial of Education And Compliance in Heart dysfunction chronic disease and heart failure (HF) as an increasing problem.
    Gwadry-Sridhar F; Guyatt G; O'Brien B; Arnold JM; Walter S; Vingilis E; MacKeigan L
    Contemp Clin Trials; 2008 Nov; 29(6):905-18. PubMed ID: 18703166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    Tang PA; Bentzen SM; Chen EX; Siu LL
    J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.